Trial Profile

A randomised controlled trial of alternative treatments to inhibit VEGF in age-related choroidal neovascularisation

Status: Completed

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 27 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Ranibizumab
Indications Choroidal neovascularisation; Wet age-related macular degeneration
Focus Therapeutic Use
Acronyms IVAN

Most Recent Events

26 Apr 2022 New trial record
01 Apr 2022 Results (n=535) of Secondary analyses comparing demographics, visual acuity and retinal morphology between those with, and without baseline submacular hemorrhage, published in the American Journal of Ophthalmology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com